Modified PISA assay identifies TNFα as the antigen for infliximab in monocytes, suggesting new detection strategies.
The Proteome Integral Solubility Alteration (PISA) assay is commonly used to identify and characterize interactions between small molecules and the cellular proteome. In this study, a modified PISA approach identified tumor necrosis factor alpha (TNFα) as the antigen of the monoclonal antibody infliximab in activated monocytes - uniquely among ~8,000 cellular proteins. These results highlight the potential of PISA-based analysis not only for monitoring antibody-antigen interactions in therapeutic development, but also for identifying new antigens and characterizing the initial effector functions of antibodies within complex proteome environments.
No takes yet. Share an insight, caveat, or question.
Zubarev et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: